Drugs / PRT1419
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05107856 | Mar 2022 → Jan 2024 | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myelomonocytic leukemia, follicular lymphoma +3 | Prelude Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04837677 | Aug 2021 → Feb 2023 | breast cancer, cervical cancer, esophageal cancer, head and neck cancer +3 | Prelude Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04543305 | Sep 2020 → Mar 2022 | acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, plasma cell myeloma | Prelude Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-04-11 | Prelude Therapeutics | Results Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference preludetx.com ↗ |
| 2022-03-09 | Prelude Therapeutics | Results Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting preludetx.com ↗
The abstract highlights new preclinical data demonstrating synergistic benefit when PRT1419 was combined with the Company’s novel and selective SMARCA2 degrader, PRT3789, in SMARCA4 deleted lung cancer models. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-11 | Prelude Therapeutics | Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference preludetx.com ↗ |
| 2022-03-09 | Prelude Therapeutics | Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting preludetx.com ↗ |
| 2020-09-30 | Prelude Therapeutics | Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies preludetx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT1419 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05107856 ↗ |
| Action | Inhibit | “a myeloid cell leukemia 1 (MCL1) inhibitor” NCT04543305 ↗ |
| Route | Oral | “PRT1419 will be administered orally” NCT04543305 ↗ |
| Target | MCL1 | “a myeloid cell leukemia 1 (MCL1) inhibitor” NCT04543305 ↗ |